AntagomiR-based therapy for pulmonary arterial hypertension: MIRNA-7 increases pulmonary arterial hypertension via down regulation of its target gene, 11/February/2015, 23.07

Molecular therapy for Inflammatory Bowel disease (IBD): PCBP2 preserves the functions of Beclin 1 and ATG5 and decreases tissue injury in inflammatory bowel disease (IBD) via down regulation of its target gene, 11/February/2015, 22.57
February 11, 2015
Molecular therapy for T2DM: β-catenin promotes gluconeogenesis and hyperglycemia via up regulation of Cyclin D1, 11/February/2014, 23.19
February 11, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that MiRNA-7, by suppressing the expression of its target gene, it may increase pulmonary arterial hypertension. Thus, pharmacological formulations encompassing “MiRNA-7 inhibitors may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 300*

Undisclosed information: How MiRNA-7  increases pulmonary arterial hypertension

To citeBoominathan, AntagomiR-based therapy for pulmonary arterial hypertension: MIRNA-7 increases  pulmonary arterial hypertension via down regulation of its target gene, 11/February/2015,  23.07,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.